Blood pressure pill showdown pulled before it began
NCT ID NCT02483936
First seen Dec 12, 2025
Summary
This study aimed to compare two different combination pills for controlling high blood pressure: one with olmesartan and chlorthalidone, and another with olmesartan and hydrochlorothiazide (Benicar HCT). The trial was planned for people with uncontrolled hypertension but was withdrawn before any participants were enrolled. No results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olmesartan medoxomil + chlorthalidone
What this could lead to
If successful, this could offer a new fixed-dose combination pill for controlling high blood pressure.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safer or more effective than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.